Correspondence
Counter reply in reference to “Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine”
Respuesta a la carta al Director sobre «Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer–BioNTech) en trabajadores sanitarios»
A.C. Montaguda, J. Llenas-Garcíab,c,d, R. Moraguese, A. Pérez-Bernabeub,d, M.J. Alcocer Pertegalf, F.J. García Gómezg, A.M. Gamayo Sernag, H. García Moranteb,d, P. Caballeroe, J. Tuellse,h,
Corresponding author
a Laboratorio de Inmunología, Plataforma Oncológica, Hospital QuironSalud Torrevieja, Alicante, Spain
b Servicio de Medicina Interna, Hospital Vega Baja, Orihuela, Alicante, Spain
c Departamento de Medicina Clínica, Universidad Miguel Hernández, Elche, Alicante, Spain
d Fundación para la Promoción de la Salud e Investigación Biomédica de Valencia, FISABIO, Valencia, Spain
e Departamento de Enfermería Comunitaria, Medicina Preventiva, Salud Pública e Historia de la Ciencia, Universidad de Alicante, Alicante, Spain
f Dirección de Enfermería de Atención Primaria, Departamento de Salud de Orihuela, Alicante, Spain
g Dirección de Enfermería Hospitalaria, Hospital Vega Baja, Alicante, Spain
h Instituto de Salud e Investigación Biomédica de Alicante, (ISABIAL), Alicante, Spain
Read
499
Timeswas read the article
2
Total PDF
497
Total HTML
Share statistics
array:23 [ "pii" => "S2254887424000857" "issn" => "22548874" "doi" => "10.1016/j.rceng.2024.06.006" "estado" => "S300" "fechaPublicacion" => "2024-08-01" "aid" => "2216" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2024;224:482-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0014256524001139" "issn" => "00142565" "doi" => "10.1016/j.rce.2024.06.001" "estado" => "S300" "fechaPublicacion" => "2024-08-01" "aid" => "2216" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2024;224:482-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Correspondencia</span>" "titulo" => "Respuesta a la carta al Director sobre «Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer–BioNTech) en trabajadores sanitarios»" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "482" "paginaFinal" => "483" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Counter reply in reference to “Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine”" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A.C. Montagud, J. Llenas-García, R. Moragues, A. Pérez-Bernabeu, M.J. Alcocer Pertegal, F.J. García Gómez, A.M. Gamayo Serna, H. García Morante, P. Caballero, J. Tuells" "autores" => array:10 [ 0 => array:2 [ "nombre" => "A.C." "apellidos" => "Montagud" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Llenas-García" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "Moragues" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Pérez-Bernabeu" ] 4 => array:2 [ "nombre" => "M.J." "apellidos" => "Alcocer Pertegal" ] 5 => array:2 [ "nombre" => "F.J." "apellidos" => "García Gómez" ] 6 => array:2 [ "nombre" => "A.M." "apellidos" => "Gamayo Serna" ] 7 => array:2 [ "nombre" => "H." "apellidos" => "García Morante" ] 8 => array:2 [ "nombre" => "P." "apellidos" => "Caballero" ] 9 => array:2 [ "nombre" => "J." "apellidos" => "Tuells" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2254887424000857" "doi" => "10.1016/j.rceng.2024.06.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887424000857?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256524001139?idApp=WRCEE" "url" => "/00142565/0000022400000007/v1_202408020450/S0014256524001139/v1_202408020450/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2254887424000900" "issn" => "22548874" "doi" => "10.1016/j.rceng.2024.06.011" "estado" => "S300" "fechaPublicacion" => "2024-08-01" "aid" => "2214" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2024;224:481" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Correspondence</span>" "titulo" => "Letter to the Editor about “Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers before the booster dose of the vaccine”" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "481" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Carta replica a “Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer–BioNTech) en trabajadores sanitarios”" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "H. Daungsupawong, V. Wiwanitkit" "autores" => array:2 [ 0 => array:2 [ "nombre" => "H." "apellidos" => "Daungsupawong" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Wiwanitkit" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256524001115" "doi" => "10.1016/j.rce.2024.05.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256524001115?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887424000900?idApp=WRCEE" "url" => "/22548874/0000022400000007/v1_202408020531/S2254887424000900/v1_202408020531/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Correspondence</span>" "titulo" => "Counter reply in reference to “Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine”" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "482" "paginaFinal" => "483" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A.C. Montagud, J. Llenas-García, R. Moragues, A. Pérez-Bernabeu, M.J. Alcocer Pertegal, F.J. García Gómez, A.M. Gamayo Serna, H. García Morante, P. Caballero, J. Tuells" "autores" => array:10 [ 0 => array:3 [ "nombre" => "A.C." "apellidos" => "Montagud" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Llenas-García" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 2 => array:3 [ "nombre" => "R." "apellidos" => "Moragues" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 3 => array:3 [ "nombre" => "A." "apellidos" => "Pérez-Bernabeu" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "M.J." "apellidos" => "Alcocer Pertegal" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 5 => array:3 [ "nombre" => "F.J." "apellidos" => "García Gómez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 6 => array:3 [ "nombre" => "A.M." "apellidos" => "Gamayo Serna" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 7 => array:3 [ "nombre" => "H." "apellidos" => "García Morante" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 8 => array:3 [ "nombre" => "P." "apellidos" => "Caballero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 9 => array:4 [ "nombre" => "J." "apellidos" => "Tuells" "email" => array:1 [ 0 => "tuells@ua.es" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:8 [ 0 => array:3 [ "entidad" => "Laboratorio de Inmunología, Plataforma Oncológica, Hospital QuironSalud Torrevieja, Alicante, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Vega Baja, Orihuela, Alicante, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Departamento de Medicina Clínica, Universidad Miguel Hernández, Elche, Alicante, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Fundación para la Promoción de la Salud e Investigación Biomédica de Valencia, FISABIO, Valencia, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Departamento de Enfermería Comunitaria, Medicina Preventiva, Salud Pública e Historia de la Ciencia, Universidad de Alicante, Alicante, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Dirección de Enfermería de Atención Primaria, Departamento de Salud de Orihuela, Alicante, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Dirección de Enfermería Hospitalaria, Hospital Vega Baja, Alicante, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Instituto de Salud e Investigación Biomédica de Alicante, (ISABIAL), Alicante, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Respuesta a la carta al Director sobre «Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer–BioNTech) en trabajadores sanitarios»" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We are grateful for the comments made on our article published in Revista Clínica Española<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> and would like to respond to the questions raised. Our epidemiological study describes the humoral immunity associated with the prevalence of SARS-CoV-2 neutralizing antibodies induced after two doses of the BNT162b2 vaccine (Pfizer-BioNTech) in a healthcare population. This professional group was of priority interest in Spain, as can be seen in the vaccination strategies. In general, they were administered doses of the BNT162b2 vaccine (Pfizer-BioNTech), as reflected in our study, since 97.5% of the participating subjects received this type of vaccine. The response to other types of vaccines was considered in a similar study in another population.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">As our results show, of the approximately 1500 health workers in the healthcare area, 90.1% (1352/1500) were contacted. Of them, 72.3% (977/1352) participated in the serological tests and 98.7% (964/977) of those answered the questionnaire in its entirety. Participation was voluntary, so the demographic and clinical data obtained from the total sample corresponds to 64.3% (964/1500) of the total number of workers in the healthcare area. It is a representative sample, given that the estimated sample size for a finite population such as that of this study (1500), considering an estimation of ±3%, and assuming in the most unfavorable case a prevalence of 0.5 and a significance of 0.05, 625 subjects would be needed, a value widely exceeded in our study. Participant selection was not random but by flooding, all healthcare personnel were invited to participate. Considering that the vast majority of this at-risk group was vaccinated, whether there was antibody positivity or not was not voluntary, thus minimizing possible selection bias.</p><p id="par0015" class="elsevierStylePara elsevierViewall">In regard to the statement that the study did not provide information on specific characteristics of participants who were positive for antibodies, table 2<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> reports the variables for this group such as: age, sex, time since last dose, previous SARS-CoV-2 infection, comorbidity, other recent infections, type of vaccine received, and number of doses administered. This contradicts the statement made later in the letter: “The study did not investigate other potential factors that may have an influence on the presence of neutralizing antibodies, such as the vaccine type or underlying health conditions”.</p><p id="par0020" class="elsevierStylePara elsevierViewall">A total of 18.2% of the subjects had a chronic disease that could have affected antibody production, as in the case of diseases that cause compromised immunity<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> (cancer, immunosuppressed patients, etc.), which could influence the presence or absence of neutralizing antibodies. This possible influence was not significant in our study.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Increasing the participation rate would not ensure greater representativeness for a population group in which the vaccination effect has occurred in all participants. The following statement, “it should be considered whether to explore additional factors that may influence the presence of antibodies, such as the type of vaccine, comorbidities, or variations in the immune response”, is redundant and has been answered above.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:3 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalencia de anticuerpos neutralizantes frente al SARS-CoV-2 inducidos tras 2 dosis de vacuna BNT162b2 (Pfizer–BioNTech) en trabajadores sanitarios" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.C. Montagud" 1 => "J. Llenas-García" 2 => "R. Moragues" 3 => "A. Pérez-Bernabeu" 4 => "M.J.A. Pertegal" 5 => "F.J.G. Gómez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rce.2024.01.009" "Revista" => array:7 [ "tituloSerie" => "Rev Clin Esp" "fecha" => "2024" "volumen" => "224" "numero" => "4" "paginaInicial" => "197" "paginaFinal" => "203" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/38423384" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 vaccination at the University of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.C. Montagud" 1 => "N. Vicente-Alcalde" 2 => "E.M. Gabaldón-Bravo" 3 => "J.A. Hurtado-Sánchez" 4 => "E. Montagud" 5 => "C.M. Egoavil" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Rev Esp Salud Publica" "fecha" => "2023" "volumen" => "97" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Galmiche" 1 => "L.B. Luong Nguyen" 2 => "E. Tartour" 3 => "X. de Lamballerie" 4 => "L. Wittkop" 5 => "P. Loubet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2021.09.036" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2022" "volumen" => "28" "paginaInicial" => "163" "paginaFinal" => "177" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35020589" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22548874/0000022400000007/v1_202408020531/S2254887424000857/v1_202408020531/en/main.assets" "Apartado" => array:4 [ "identificador" => "71813" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Correspondence" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22548874/0000022400000007/v1_202408020531/S2254887424000857/v1_202408020531/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887424000857?idApp=WRCEE" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 October | 32 | 0 | 32 |
| 2024 September | 55 | 0 | 55 |
| 2024 August | 59 | 0 | 59 |
| 2024 July | 339 | 2 | 341 |
| 2024 June | 12 | 0 | 12 |
